318 related articles for article (PubMed ID: 28282997)
1. Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register.
Yassin A; Salman M; Talib RA; Yassin DJ
Aging Male; 2017 Jun; 20(2):125-133. PubMed ID: 28282997
[TBL] [Abstract][Full Text] [Related]
2. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy.
Shoskes DA; Barazani Y; Fareed K; Sabanegh E
Int Braz J Urol; 2015; 41(6):1167-71. PubMed ID: 26742976
[TBL] [Abstract][Full Text] [Related]
4. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
Rhoden EL; Morgentaler A
J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
[TBL] [Abstract][Full Text] [Related]
5. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
7. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
8. Testosterone Therapy in Patients with Treated and Untreated Prostate Cancer: Impact on Oncologic Outcomes.
Ory J; Flannigan R; Lundeen C; Huang JG; Pommerville P; Goldenberg SL
J Urol; 2016 Oct; 196(4):1082-9. PubMed ID: 27131465
[TBL] [Abstract][Full Text] [Related]
9. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.
Haider A; Zitzmann M; Doros G; Isbarn H; Hammerer P; Yassin A
J Urol; 2015 Jan; 193(1):80-6. PubMed ID: 24980615
[TBL] [Abstract][Full Text] [Related]
10. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
[TBL] [Abstract][Full Text] [Related]
11. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.
Bhasin S; Travison TG; Pencina KM; O'Leary M; Cunningham GR; Lincoff AM; Nissen SE; Lucia MS; Preston MA; Khera M; Khan N; Snabes MC; Li X; Tangen CM; Buhr KA; Thompson IM
JAMA Netw Open; 2023 Dec; 6(12):e2348692. PubMed ID: 38150256
[TBL] [Abstract][Full Text] [Related]
12. Testosterone replacement therapy and the risk of prostate cancer.
Warburton D; Hobaugh C; Wang G; Lin H; Wang R
Asian J Androl; 2015; 17(6):878-81; discussion 880. PubMed ID: 25865848
[TBL] [Abstract][Full Text] [Related]
13. Testosterone replacement therapy in the setting of prostate cancer treated with radiation.
Pastuszak AW; Pearlman AM; Godoy G; Miles BJ; Lipshultz LI; Khera M
Int J Impot Res; 2013 Jan; 25(1):24-8. PubMed ID: 22971614
[TBL] [Abstract][Full Text] [Related]
14. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
Rhoden EL; Morgentaler A
Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
[TBL] [Abstract][Full Text] [Related]
15. Testosterone replacement therapy in men with prostate cancer: a time-varying analysis.
Kaplan AL; Lenis AT; Shah A; Rajfer J; Hu JC
J Sex Med; 2015 Feb; 12(2):374-80. PubMed ID: 25496237
[TBL] [Abstract][Full Text] [Related]
16. Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer.
Hashimoto T; Rahul K; Takeda T; Benfante N; Mulhall JP; Hricak H; Eastham JA; Vargas HA
Urol Oncol; 2016 Dec; 34(12):530.e9-530.e14. PubMed ID: 27665357
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
Morgentaler A; Rhoden EL
Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
[TBL] [Abstract][Full Text] [Related]
18. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms.
Leibowitz RL; Dorff TB; Tucker S; Symanowski J; Vogelzang NJ
BJU Int; 2010 May; 105(10):1397-401. PubMed ID: 19912179
[TBL] [Abstract][Full Text] [Related]
19. Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer.
Dai B; Qu Y; Kong Y; Ye D; Yao X; Zhang S; Wang C; Zhang H; Yang W
BJU Int; 2012 Dec; 110(11 Pt B):E667-72. PubMed ID: 22974446
[TBL] [Abstract][Full Text] [Related]
20. The role of testosterone replacement therapy following radical prostatectomy.
Khera M; Lipshultz LI
Urol Clin North Am; 2007 Nov; 34(4):549-53, vi. PubMed ID: 17983894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
